Manmeet Ahluwalia was named deputy director, chief scientific officer and chief of solid tumor medical oncology at Baptist Health’s Miami Cancer Institute.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
